Our Leadership

Our accomplished leadership team has a successful track-record of discovering, developing and commercializing breakthrough therapeutics for the disease indications we are pursuing. We are deeply committed to leveraging our platform technology to develop novel C1q inhibitors for the treatment of patients with antibody-mediated autoimmune and complement-mediated neurodegenerative diseases.

Douglas Love Esq

PRESIDENT & CHIEF EXECUTIVE OFFICER

Ted Yednock PhD

EVP & CHIEF SCIENTIFIC OFFICER

Jennifer Lew

EVP & CHIEF FINANCIAL OFFICER

Sanjay Keswani MBBS, FRCP

EVP & CHIEF MEDICAL OFFICER
Board of Directors Scientific Advisors Founders Investors